Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy
2017-001590-16Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tilavonemab in progressive supranuclear palsy (PSP), sponsored by AbbVie Inc. Primary endpoint: Change in Progressive Supranuclear Palsy Rating Scale (PSPRS). Started Jan 2019; status: terminated.
02
Drugs
tilavonemab
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on 2017-001590-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001590-16.